Cardinal Health (NYSE:CAH) Stock Price Expected to Rise, Mizuho Analyst Says

Cardinal Health (NYSE:CAH) had its price objective hoisted by analysts at Mizuho from $235.00 to $240.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s price target would indicate a potential upside of 7.53% from the company’s previous close.

CAH has been the subject of a number of other research reports. Wall Street Zen raised shares of Cardinal Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 4th. Citigroup reaffirmed a “buy” rating on shares of Cardinal Health in a research report on Thursday, July 2nd. UBS Group lifted their price objective on Cardinal Health from $260.00 to $274.00 and gave the stock a “buy” rating in a research report on Monday. Evercore dropped their price objective on Cardinal Health from $260.00 to $240.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. Finally, TD Cowen upped their target price on Cardinal Health from $255.00 to $275.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Fifteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $250.40.

Cardinal Health Trading Up 1.2%

NYSE:CAH traded up $2.66 on Thursday, reaching $223.20. 414,708 shares of the stock traded hands, compared to its average volume of 2,026,834. The firm has a market capitalization of $52.27 billion, a price-to-earnings ratio of 34.10, a price-to-earnings-growth ratio of 1.11 and a beta of 0.49. The company’s 50 day moving average is $218.69 and its 200-day moving average is $214.20. Cardinal Health has a 1-year low of $137.75 and a 1-year high of $243.21.

Cardinal Health (NYSE:CAH) last released its quarterly earnings results on Thursday, April 30th. The company reported $3.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.79 by $0.38. The firm had revenue of $60.94 billion during the quarter, compared to analyst estimates of $62.10 billion. Cardinal Health had a net margin of 0.62% and a negative return on equity of 92.61%. The company’s revenue was up 11.0% compared to the same quarter last year. During the same quarter last year, the business earned $2.35 EPS. Cardinal Health has set its FY 2026 guidance at 10.700-10.80 EPS. On average, equities research analysts forecast that Cardinal Health will post 10.77 EPS for the current fiscal year.

Institutional Investors Weigh In On Cardinal Health

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Investors Research Corp bought a new position in shares of Cardinal Health during the 2nd quarter worth about $29,000. University of Texas Texas AM Investment Management Co. acquired a new position in Cardinal Health during the 4th quarter worth approximately $26,000. Allied Private Wealth LLC acquired a new position in Cardinal Health during the 2nd quarter worth approximately $30,000. Bank of Jackson Hole Trust bought a new position in Cardinal Health in the fourth quarter worth approximately $27,000. Finally, Indiana Trust & Investment Management Co acquired a new stake in Cardinal Health in the first quarter valued at approximately $29,000. 87.17% of the stock is owned by institutional investors.

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.